Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01332227 · ClinicalTrials.gov registry record · Phase 4
Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
A Phase 4 study of HIV, Combination Therapy, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 132
- Enrollment target
- 20
- Study locations
NCT01332227 is a Phase 4 study of HIV, Combination Therapy that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 132 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT01332227, a Phase 4 study of HIV, Combination Therapy, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 132 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether HIV-1-infected patients, who are virologically suppressed on a regimen of 2 nucleoside reverse transcriptase inhibitors plus any third agent but are experiencing safety and/or tolerability issues, will maintain virologic suppression after switching to a regimen of heat-stable ritonavir boosted atazanavir, 300/100 mg, once daily plus raltegravir, 400 mg, twice daily.
Conditions Studied
Interventions
- DRUG Atazanavir
- DRUG Raltegravir
- DRUG Ritonavir (heat-stable)
- DRUG Tenofovir/Emtricitabine
Study Locations (20)
Other
- Local Institution - Lyon
- Local Institution - Orléans
- Local Institution - Paris
- Local Institution - Paris
- Local Institution - Strasbourg
- Local Institution - Bochum
- Local Institution - Frankfurt
- Local Institution - Frankfurt am Main
- Local Institution - Hamburg
- Local Institution - Munich
- Local Institution - Genova
Florida
- Consultive Medicine - Daytona Beach
- Orange County Health Dept. - Orlando
- Triple O Medical Services, P.A. - West Palm Beach
California
- Eisenhower Medical Center - Palm Springs
- Metropolis Medical Pc - San Francisco
Arkansas
- Health For Life Clinic Pllc - Little Rock
Massachusetts
- The Research Institute - Springfield
New York
- Aids Care - Rochester
Cedex 12
- Local Institution - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01332227
The ClinicalTrials.gov registry entry for NCT01332227 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV, Combination Therapy appearing as the primary indexed condition, and to 4 interventions - of which Atazanavir is the first listed.
NCT01332227 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT01332227 about?
NCT01332227 is a clinical study titled "Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients". The purpose of this study is to determine whether HIV-1-infected patients, who are virologically suppressed on a regimen of 2 nucleoside reverse transcriptase inhibitors plus any third agent but are experiencing safety and/or tolerability issues, will maintain virologic suppression after switching t...
What is the current status of trial NCT01332227?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 132 participants. The study started on 2011-10. Estimated completion is 2014-02.
What conditions does trial NCT01332227 study?
This clinical trial studies the following conditions: HIV, Combination Therapy.
What interventions are being tested in trial NCT01332227?
The interventions under investigation include: Atazanavir (DRUG), Raltegravir (DRUG), Ritonavir (heat-stable) (DRUG), Tenofovir/Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT01332227?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01332227 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.